Bloodless medicine: What to do when you can't transfuse

Hematology (United States)

Volumn 2014, Issue 1, 2014, Pages 553-558

  Resar, Linda M S ^a   Frank, Steven M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; BLOODLESS CARE; CHILD; HEALTH CARE PLANNING; HUMAN;

BLOOD TRANSFUSION; BLOODLESS MEDICAL AND SURGICAL PROCEDURES; CHILD; HEALTH PLANNING GUIDELINES; HUMANS;

EID: 84937578827     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2014.1.553     Document Type: Article

References (41)

1. Farrugia A. Falsification or paradigm shift? Toward a revision of the common sense of transfusion. Transfusion. 2011;51(1):216-224.
2. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Transfusion. 2013;53(4):888-901.
3. Waters JH, Ness PM. Patient blood management: a growing challenge and opportunity. Transfusion. 2011;51(5):902-903.
4. Frank SM, Wick EC, DeZern AE, et al. Risk-adjusted outcomes in patients enrolled in a bloodless program. Transfusion. Prepublished on June 18, 2014, as DOI 10.1111/trf.12752.
5. McCartney S, Guinn N, Roberson R, Broomer B, White W, Hill S. Jehovah's Witnesses and cardiac surgery: a single institution's experience. Transfusion. Prepublished on May 9, 2014, as DOI 10.1111/trf.12696.
6. Angouras DC. Jehovah's Witnesses may not have identical outcomes with nontransfused non-witnesses after cardiac surgery. JAMA Intern Med. 2013;173(3):248-249.
7. Vaislic CD, Dalibon N, Ponzio O, et al. Outcomes in cardiac surgery in 500 consecutive Jehovah's Witness patients: 21 year experience. J Cardiothorac Surg. 2012;7:95.
8. Jassar AS, Ford PA, Haber HL, et al. Cardiac surgery in Jehovah's Witness patients: ten-year experience. Ann Thorac Surg. 2012;93(1):19-25.
9. Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Intern Med. 2012;172(15):1154-1160.
10. Emmert MY, Salzberg SP, Theusinger OM, et al. How good patient blood management leads to excellent outcomes in Jehovah's Witness patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg. 2011;12(2):183-188.
11. Bhaskar B, Jack RK, Mullany D, Fraser J. Comparison of outcome in Jehovah's Witness patients in cardiac surgery: an Australian experience. Heart Lung Circ. 2010;19(11):655-659.
12. Juraszek A, Dziodzio T, Roedler S, et al. Results of open heart surgery in Jehovah's Witnesses patients. J Cardiovasc Surg. 2009;50(2):247-250.
13. Casati V, D'Angelo A, Barbato L, et al. Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery. Br J Anaesth. 2007;99(3):349-352.
14. Reyes G, Nuche JM, Sarraj A, et al. [Bloodless cardiac surgery in Jehovah's witnesses: outcomes compared with a control group]. Rev Esp Cardiol. 2007;60(7):727-731. Article in Spanish.
15. Stamou SC, White T, Barnett S, Boyce SW, Corso PJ, Lefrak EA. Comparisons of cardiac surgery outcomes in Jehovah's versus non-Jehovah's Witnesses. Am J Cardiol. 2006;98(9):1223-1225.
16. Helm RE, Rosengart TK, Gomez M, et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg. 1998;65(1):125-136.
17. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002;42(7):812-818.
18. Goodnough LT. Blood management: transfusion medicine comes of age. Lancet. 2013;381(9880):1791-1792.
19. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122(23):3735-3740.
20. Chant C, Wilson G, Friedrich JO. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study. Crit Care. 2006;10(5):R140.
21. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Comparative effectiveness of revascularization strategies. N Engl J Med. 2012;336(16): 1467-1476.
22. Singla AK, Lapinski RH, Berkowitz RL, Saphier CJ. Are women who are Jehovah's Witnesses at risk of maternal death? Am J Obstet Gynecol. 2001;185(4):893-895.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
24. Stonemetz JL, Allen PX, Wasey J, et al. Development of a risk-adjusted blood utilization metric. Transfusion. In press.
25. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Statistical Software. 2011;42(7):1-52.
26. Shander A, Javidroozi M, Perelman S, et al. From bloodless surgery to patient blood management. Mt Sinai J Med. 2012;79(1):56-65.
27. Shander A, Javidroozi M, Goodnough LT. Anemia screening in elective surgery: definition, significance and patients' interests. Anesth Analg. 2006;103(3):778-779; author reply 779-780.
28. Frank SM, Resar LMS, Rothschild JA, Dackiw EA, Savage WJ, Ness PM. A novel method of data analysis for utilization of red cell transfusion. Transfusion. 2013;53(12):3052-3059.
29. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-475.
30. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-e350S.
31. Frank SM, Wasey JO, Dwyer IM, Gokaslan ZL, Ness PM, Kebaish KM. Radiofrequency bipolar hemostatic sealer reduces blood loss, transfusion requirements and cost for patients undergoing multilevel spinal fusion surgery. J Orthop Surg Res. 2014;9:50.
32. Ozier Y, Bellamy L. Pharmacologic agents: antifibrinolytics and desmopressin. Best Pract Res Clin Anaesthesiol. 2010;24(1):107-119.
33. Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother. 2007;41(9):1476-1480.
34. Meneghini L, Zadra N, Aneloni V, et al. Erythropoietin therapy and acute preoperative normovolaemic haemodilution in infants undergoing craniosynostosis surgery. Paediatr Anaesth. 2003;13(5):392-396.
35. Fearon JA, Weinthal J. The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children. Plast Reconstr Surg. 2002;109(7):2190-2196.
36. Helfaer MA, Carson BS, James CS, et al. Increased hematocrit and decreased transfusion requirements in children given erythropoietin before undergoing craniofacial surgery. J Neurosurg. 1998;88(4):704-708.
37. Vitale MG, Privitera DM, Matsumoto H. Efficacy of preoperative erythropoietin administration in pediatric neuromuscular scoliosis patients. Spine. 2007;32(24):2662-2667.
38. Vitale MG, Roye BD, Ruchelsman DE, Roye DP Jr. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes. Spine J. 2007(3);7:292-300.
39. Shermock KM, Horn E, Rice TL. Erythropoietic agents for anemia of critical illness. Am J Health Syst Pharm. 2008;65(6):540-546.
40. Lindholm J, Palmér K, Frenckner B. Long-term ECMO treatment in Jehovah's Witness patient without transfusions. Perfusion. 2012;27(4): 332-334.
41. Lanzkron S, Moliterno AR, Norris EJ, et al. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion. 2002;42(11):1422-1427.